Renovaro INC 8-K filings

GEDi Cube B.V., a subsidiary of Renovaro Inc., has amended and restated its employment agreement with CEO Maurice van Tilburg, outlining his compensation and benefits.

Renovaro Inc. has appointed Nathen Fuentes as its new Chief Financial Officer, effective January 6, 2025, replacing Simon Tarsh who served as interim CFO.

Renovaro Inc. has announced a binding letter of intent to acquire Predictive Oncology Inc. in an all-stock transaction, aiming to combine their AI platforms and biobank resources for enhanced cancer diagnostics and drug discovery.

Renovaro Inc. has appointed Maurice van Tilburg as the new CEO of its subsidiary, GEDi Cube, effective immediately, with a base salary of $300,000 per year and potential bonuses and equity incentives.

Renovaro Inc.'s Chief Operating Officer, Francois Binette PhD, has resigned, effective November 22, 2024.

Renovaro Inc. has amended its consulting agreement with Tarsh PB Advisors, detailing compensation and bonus structures for Interim CFO Simon Tarsh.

Renovaro Inc. has filed an amendment to its previous 8-K report to provide details on the committee appointments of its newly appointed directors.

Renovaro Inc. has appointed a new CEO, David Weinstein, and significantly restructured its board of directors following the resignation of several key members.

Renovaro Inc. has been notified by Nasdaq that its stock price has fallen below the minimum bid price requirement for continued listing.

Renovaro Inc. is seeking strategic investors to acquire up to 20% of its wholly-owned subsidiary, Cube, a molecular data science company focused on AI-driven precision medicine.

Renovaro Inc. will restate its Q1 2024 financials due to a material misstatement related to the valuation of its indefinite life intangible assets.

Renovaro Inc. reports the resignation of Leni Boeren from its Board of Directors, effective June 27, 2024, due to family health reasons.

Renovaro Inc. has successfully completed a private placement, raising $10 million through the sale of units consisting of common stock and warrants.

Renovaro Inc.'s Board of Directors approved an amendment and restatement of the company's bylaws, updating the company name and corporate officer titles.

Renovaro Inc. and the Amsterdam UMC Cancer Center have announced a partnership to form a joint company focused on developing personalized cancer immunotherapy.

RenovaroCube, a subsidiary of Renovaro Inc., has launched Flamingo, a novel AI model utilizing fragmentomics for improved multi-cancer detection through analysis of cell-free DNA.

RenovaroCube will acquire full ownership of Cyclomics, enhancing their combined capabilities in AI-driven cancer diagnostics and treatment.

Renovaro Inc. has finalized its acquisition of Renovaro Cube and filed an amended 8-K report including audited financials and pro forma statements.

Renovaro Inc. has appointed Simon Tarsh as Interim Chief Financial Officer, effective March 11, 2024, and entered into a consulting agreement with his firm, Tarsh PB Advisors LLC.

Renovaro Inc. has received notice of termination for a key license agreement related to its HIV program, prompting a shift in focus towards its cancer vaccine candidate.

Renovaro Inc. has announced the resignation of its Chief Financial Officer, Luisa Puche, effective March 21, 2024, with plans for a smooth transition.

Renovaro Inc. announced it has received commitments for $3 million in additional equity, expected to close on February 20, 2024.

Renovaro Inc. has completed its acquisition of GEDi Cube Intl Ltd., combining AI and biotech platforms to accelerate personalized medicine.

Renovaro Biosciences has increased its authorized share capital from 110 million to 360 million shares, effective February 1, 2024, following shareholder approval.

Renovaro Biosciences successfully obtained shareholder approval for all proposals at its special meeting, including those related to a stock purchase agreement and an increase in authorized shares.

Renovaro Biosciences has amended its proxy statement related to the acquisition of GEDi Cube following demand letters from purported shareholders alleging disclosure deficiencies.

Renovaro Biosciences is making strides in AI-driven diagnostics and cancer vaccine development, while also planning a merger with AI firm GEDi Cube.